RADX revenueFY2026$2.77M
- FY YoY
- -23.8%
RADX revenue was $2.77M for fiscal 2026 (ended Jun 30, 2026), down 23.8% from fiscal 2025. It rose in 2 of the last 3 fiscal years.
Radiopharm Theranostics Limited (RADX) financials
For fiscal 2026 (ended Jun 30, 2026), Radiopharm Theranostics Limited reported $2.77M of revenue and -$56.95M of net income.
- Revenue, FY2026
- $2.77M
- Revenue growth, YoY
- -23.8%
- Net income, FY2026
- -$56.95M
- Net margin
- -2057.5%
- EPS, diluted, FY2026
- -$1.79
- Cash
- $4.14M
- P/S
- 4.64
- Market cap
- $12.9M
FY2023FY2026
FY2023FY2026
RADX revenue and earnings growth
RADX net incomeFY2026-$56.95M
RADX net income was -$56.95M for fiscal 2026 (ended Jun 30, 2026), compared with -$38.34M in fiscal 2025.
RADX EPSFY2026-$1.79
RADX diluted EPS was -$1.79 for fiscal 2026 (ended Jun 30, 2026).
Income statement
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 |
|---|---|---|---|---|
| Revenue | $2.77M | $3.63M | $299.2K | $292.4K |
| Cost of revenue | $2.50M | $3.59M | - | - |
| Gross profit | $263.4K | $39.3K | $299.2K | $292.4K |
| Research and development | $49.96M | $27.52M | $23.09M | $22.63M |
| Selling, general and admin | $16.22M | $14.64M | $13.04M | $12.23M |
| Operating income | -$56.78M | -$38.17M | -$47.21M | -$34.49M |
| Interest expense | $112.4K | $65.3K | $642.9K | $86.1K |
| Pre-tax income | -$56.90M | -$38.24M | -$47.85M | -$34.57M |
| Income tax | $54.4K | $103.3K | $96.4K | $38.0K |
| Net income | -$56.95M | -$38.34M | -$47.95M | -$34.61M |
| EPS, basic | -$1.79 | -$1.76 | -$12.41 | -$11.32 |
| EPS, diluted | -$1.79 | -$1.76 | -$12.41 | -$11.32 |
| Diluted shares | 3.07B | 2.08B | 386.5M | 305.8M |
Balance sheet
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 |
|---|---|---|---|---|
| Cash and equivalents | $4.14M | $29.12M | $18.58M | $11.70M |
| Receivables | $17.45M | $10.40M | $987.4K | $4.47M |
| Current assets | $21.93M | $39.85M | $22.85M | - |
| Total assets | $60.13M | $86.48M | $72.04M | - |
| Current liabilities | $18.90M | $14.93M | $17.58M | - |
| Total liabilities | $37.81M | $43.61M | $44.68M | - |
| Shareholders' equity | $22.32M | $42.87M | $27.35M | $45.58M |
Cash flow
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 |
|---|---|---|---|---|
| Operating cash flow | -$52.78M | -$36.65M | -$22.98M | -$23.20M |
| Capital expenditures | - | - | - | $45.3K |
| Free cash flow | - | - | - | -$23.25M |
| Investing cash flow | -$5.42M | $1.77M | -$320.0K | -$1.53M |
| Financing cash flow | $33.37M | $45.43M | $30.20M | $9.22M |
| Stock-based compensation | $2.41M | $1.90M | $2.64M | $3.04M |
| Depreciation and amortization | $2.71M | $2.60M | $3.13M | $3.30M |
Key ratios
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 |
|---|---|---|---|---|
| Revenue growth, YoY | -23.8% | 1114.3% | 2.3% | - |
| Gross margin | 9.5% | 1.1% | 100.0% | 100.0% |
| Operating margin | -2051.5% | -1050.6% | -15777.2% | -11796.1% |
| Net margin | -2057.5% | -1055.3% | -16024.3% | -11838.6% |
| Free cash flow margin | - | - | - | -7951.6% |
| Return on equity | -255.1% | -89.4% | -175.3% | -75.9% |
| Return on assets | -94.7% | -44.3% | -66.6% | - |
| Current ratio | 1.16 | 2.67 | 1.30 | - |
Source: XBRL data Radiopharm Theranostics Limited files with the SEC, latest filing dated Sep 30, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
RADX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| RADX | $2.77M | -23.8% | -$56.95M | -2057.5% | $12.9M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
RADX FAQ
8 questionsWhat is RADX revenue?
Radiopharm Theranostics Limited (RADX) reported $2.77M of revenue for fiscal 2026 (ended Jun 30, 2026). That is down 23.8% from the year before.Is RADX profitable?
No. Radiopharm Theranostics Limited reported a net loss of $56.95M for fiscal 2026 (ended Jun 30, 2026).How much cash and debt does RADX have?
Radiopharm Theranostics Limited reported $4.14M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is RADX revenue growing?
Radiopharm Theranostics Limited's revenue changed -23.8% in fiscal 2026, to $2.77M.What is RADX gross margin?
Radiopharm Theranostics Limited's gross profit was $263.4K on $2.77M of revenue for fiscal 2026 (ended Jun 30, 2026), a gross margin of 9.5%.What is RADX earnings per share?
Diluted earnings per share were -$1.79 for fiscal 2026 (ended Jun 30, 2026), from SEC filings, restated for any stock split those filings show.When did RADX last report financial results?
The latest statements here come from Radiopharm Theranostics Limited's 20-F filed on Sep 30, 2026, covering the period ended Jun 30, 2026.Where does this RADX financial data come from?
Quantisnow builds these statements from the structured XBRL data Radiopharm Theranostics Limited files with the SEC. It is provided for information only and is not investment advice.